LSBio

Hepatitis Viruses

Hepatitis viruses cause 1.3 million deaths worldwide annually, and cause liver diseases including acute and chronic infections, liver failure, cirrhosis, and hepatocellular carcinoma. These viruses are a diverse group, and can be either dsDNA viruses such as Hepatitis B virus (family Hepadnaviridae), or ssRNA viruses such as Hepatitis A (family Picornaviridae), Hepatitis C (Flaviviridae), Hepatitis D (Deltavirus) and Hepatitis E (Hepeviridae).

They all have in common their ability to infect hepatocytes and cause jaundice and liver disease (Table 1, adapted from Rasche, 2019):

  HAV HBV HCV HDV HEV
Virus family, genus Picornaviridae, Hepatovirus Hepadnaviridae, Orthohepadnavirus Flaviviridae, Hepacivirus Unassigned, Deltavirus Hepeviridae, Orthohepevirus
Genome type Positive-sense linear ssRNA Circular, partially dsDNA (full-length negative-sense, partial positive-sense), replication via reverse transcription Positive-sense linear ssRNA Viroid-like, negative-sense circular ssRNA Positive-sense linear ssRNA
Approx. genome length (nt) 7,500 3,200 9,600 1,700 7,200
Virion diameter (nm) 27-32 42 55-65 36-43 30-34
Envelope No / quasi-enveloped Yes Yes Yes No / quasi-enveloped
Course of infection Acute Acute/chronic (children 30-90%; adults <5%) Acute/chronic (80-85%) Acute/chronic (>80% if superinfection) Acute/chronic (<1%)
Predominant transmission routes Mainly faecal-oral, parenteral Vertical, parenteral, sexual Parenteral Parenteral, sexual Faecal-oral, food-borne, parenteral
Cellular receptor Unknown NTCP, heparan sulfate proteoglycans CD81, SR-B1, LDL receptor, claudin-1, occludin NTCP, heparan sulfate proteoglycans Unknown

dsDNA, double-stranded DNA; nt, nucleotide; NTCP, sodium taurocholate co-transporting polypeptide; ssRNA, single-stranded RNA.

Table 1: Properties of Hepatitis Viruses

Browse all hepatitis products →

References

  • Rasche A, et al. Evolutionary biology of human hepatitis viruses. (2019) J Hepatol. 70(3):501-520. doi.org/10.1016/j.jhep.2018.11.010
  • Cornberg M, et al. Real-world safety, effectiveness, and patient-reported outcomes in patients with chronic hepatitis C virus infection treated with glecaprevir/pibrentasvir: Data from the German Hepatitis C-Registry. (2019) The International Liver Congress, Vienna, abstract GS-07.
  • Dubuisson J, Cosset FL. Virology and cell biology of the hepatitis C virus life cycle: an update. (2014) J Hepatol. 61:S3-S13. doi.org/10.1016/j.jhep.2014.06.031
  • Kamar N, et al. Hepatitis E Virus Infection. (2014) Clin Microbiol Rev. 27(1):116-138. doi.org/10.1128/CMR.00057-13
  • Grassi G, et al. Hepatitis C virus relies on lipoproteins for its life cycle. (2016) World J Gastroenterol. 22(6):1953-1965. doi.org/10.3748/wjg.v22.i6.1953
  • Mangia A, et al. Global real-world evidence of sofosbuvir/velpatasvir as a simple-effective regimen for the treatment of chronic hepatitis C: integrated analysis of 12 clinical practice cohorts. (2019) The International Liver Congress, Vienna, abstract GS-01.
  • Marks K, Naggie S. Management of hepatitis C in 2019. (2019) JAMA. 322(4):355-356. doi.org/10.1001/jama.2019.5353
  • Mentha N, et al. A review on hepatitis D: From virology to new therapies. (2019) J Adv Res. 17:3-15. doi.org/10.1016/j.jare.2019.03.009
  • Morozov VA, Lagaye S. Hepatitis C virus: Morphogenesis, infection, and therapy. (2018) World J Hepatol. 10(2):186-212. doi.org/10.4254/wjh.v10.i2.186
  • Pierson TC, Diamond MS. The continued threat of emerging flaviviruses. (2020) Nat Microbiol. 5:796-812. doi.org/10.1038/s41564-020-0714-0
  • Webb GW, Dalton HR. Hepatitis E: an underestimated emerging threat. (2019) Ther Adv Infect Dis. 6:1-18. doi.org/10.1177/2049936119837162
  • Yuen MF, et al. Hepatitis B virus infection. (2018) Nat Rev Dis Primers. 4:18035. doi.org/10.1038/nrdp.2018.35
  • Zell R, et al. ICTV Virus Taxonomy Profile: Picornaviridae. (2017) J Gen Virol. 98:2421-2422. doi.org/10.1099/jgv.0.000911